Drug
Halobetasol clinical trials
- studies test it
- 19
- open now
- 0
- in phase 3
- 6
- first study started
- 2003
How studies write it
Studies that test it under each name
Combined with it in one product
Studies by the year they started
19 studies that test it; most in 2015 (6)
| Year | Studies |
|---|---|
| 2003 | 2 |
| 2008 | 1 |
| 2011 | 1 |
| 2014 | 1 |
| 2015 | 6 |
| 2016 | 3 |
| 2017 | 2 |
| 2019 | 1 |
| 2021 | 1 |
| 2023 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 4
- Phase 2
- 7
- Phase 3
- 6
- Phase 4
- 3
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 17 · Other 2
Bausch Health Americas, Inc. (12) · Actavis Inc. (2) · Sun Pharmaceutical Industries Limited (2) · Dermatology Consulting Services, PLLC (1) · Patel, Rita Vikram, M.D. (1) · Azidus Brasil (1)
Often tested with
Tested in the same studies.
Tazarotene (9) · Clobetasol (2) · Lotion Dosage Form (1) · Therapeutic Procedure (1) · Complementary or Alternative Medical Procedure (1)
Studies
Open first, then newest update. How each study uses halobetasol is read from its arms, and is right about nine times in ten.
Testing it · 19
- Safety and Efficacy of IDP-118 in Participants With Plaque PsoriasisCompletedPhase 3Bausch Health Americas, Inc.NCT02462122Written as IDP-118 Lotion
- Safety and Efficacy of IDP-122 in Participants With Plaque PsoriasisCompletedPhase 3Bausch Health Americas, Inc.NCT02515097Written as IDP-122 Lotion
- A Safety and Pharmacokinetics Study of IDP-122 Lotion in Pediatric Participants With Plaque PsoriasisActive, not recruitingPhase 4Bausch Health Americas, Inc.NCT03987763Written as IDP-122 Lotion
- A Safety and Pharmacokinetics Study of IDP-118 Lotion in Pediatric Participants With Plaque PsoriasisCompletedPhase 4Bausch Health Americas, Inc.NCT03988439Written as IDP-118 Lotion
- Anti-Inflammatory Effects of 0.045% Tazarotene/0.01% Halobetasol Lotion in PsoriasisCompletedPhase 4Dermatology Consulting Services, PLLCNCT06042647Written as 0.01% Halobetasol
- Multiple-Dose Pharmacokinetics and Potential for Adrenal Suppression Following Treatment With Halobetasol Spray in Patients With Plaque PsoriasisWithdrawnPhase 2Sun Pharmaceutical Industries LimitedNCT03298581Written as Halobetasol Propionate
- Safety and Efficacy of IDP-122 Lotion When Applied Topically to Subjects With Moderate to Severe Plaque PsoriasisCompletedPhase 2Bausch Health Americas, Inc.NCT02785185Written as IDP-122 Lotion
- Safety and Efficacy of IDP-118 Lotion to Ultravate® in the Treatment of Plaque PsoriasisCompletedPhase 2Bausch Health Americas, Inc.NCT02785172Written as IDP-118 Lotion
- Safety and Efficacy of IDP-118 Lotion in the Treatment of Plaque PsoriasisCompletedPhase 2Bausch Health Americas, Inc.NCT02785159Written as IDP-118 Lotion
- Safety and Efficacy of IDP-118 in the Treatment of Plaque PsoriasisCompletedPhase 3Bausch Health Americas, Inc.NCT02462070Written as IDP-118 Lotion
- Safety and Efficacy of IDP 118 in the Treatment of Plaque PsoriasisCompletedPhase 2Bausch Health Americas, Inc.NCT02045277Written as IDP-118 Lotion
- Long-Term Safety of IDP-118 Lotion in the Treatment of Plaque PsoriasisCompletedPhase 3Bausch Health Americas, Inc.NCT02462083Written as IDP-118 Lotion
- Safety and Efficacy of IDP-122 in the Treatment of Participants With Plaque PsoriasisCompletedPhase 3Bausch Health Americas, Inc.NCT02514577Written as IDP-122 Lotion
- Multiple-Dose Pharmacokinetics and Potential for Adrenal Suppression Following Treatment With Halobetasol Spray in Patients With Atopic DermatitisTerminatedPhase 2Sun Pharmaceutical Industries LimitedNCT03245385Written as Treatment with Halobetasol propionate 0.05% topical spray
- Topically Applied IDP-118 Lotion and HP Monad Lotion in Subjects With Moderate to Severe Plaque PsoriasisCompletedPhase 1Bausch Health Americas, Inc.NCT03058744Written as IDP-118 Lotion
- Assessment for Tachyphylaxis to Topical Corticosteroids in the Treatment of PsoriasisCompletedPhase 1Patel, Rita Vikram, M.D.NCT01404338Written as Halobetasol 0.05% ointment
- Effectiveness and Safety of Topical Halobetasol Propionate in the Treatment of Patients With PsoriasisCompletedPhase 2/3Azidus BrasilNCT00715975Written as halobetasol
- The Dose-response Study of Topically Delivered Halobetasol Propionate Ointment in Normal Skin in Healthy Adult SubjectsCompletedPhase 1Actavis Inc.NCT00865267Written as Ultravate® 0.05% ointment, single exposure
- Pivotal Bioequivalence Study of Topically Delivered Halobetasol Propionate Ointment in Normal Skin in Healthy Adult SubjectsCompletedPhase 1Actavis Inc.NCT00865605Written as Halobetasol Propionate 0.05% Ointment, single exposure
Given in every arm · 1 — halobetasol is usual care beside what is tested
As the comparator · 2 — what is tested is compared with halobetasol
- Safety and Efficacy of CITI-002 in Adult Patients With Moderate Grade HemorrhoidsCompletedPhase 2Citius Pharmaceuticals, Inc.NCT05348200Written as Monad 3
- Blinded Study of Topical Investigational Lotion Vs. Approved Cream in Treatment of Plaque PsoriasisCompletedPhase 2Therapeutics, Inc.NCT01166646Written as Halobetasol Proprionate Cream 0.05%
Codes
What other systems call halobetasol · ClinicalTrials.gg INT003517
- MeSH (NLM) C064466halobetasolConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) 9P6159HM7THALOBETASOLConfirmed FDA, NLM
- RxNorm 41208One source FDA
- NCI Thesaurus C61781HalobetasolOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C064466 | halobetasol | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | 9P6159HM7T | HALOBETASOL | Confirmed FDA, NLM |
| RxNorm | 41208 | — | One source FDA |
| NCI Thesaurus | C61781 | Halobetasol | One source FDA |
Also registered as halobetasol propionate (UNII 91A0K1TY3Z · RxNorm 45318).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.